SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): January 14, 2014
(Exact Name of the Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation)
|(Commission File Number)||(IRS Employer Identification No.)|
|6340 Sequence Drive, San Diego, CA||92121|
|(Address of Principal Executive Offices)||(Zip Code)|
(Registrants Telephone Number, Including Area Code)
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2)|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
|ITEM 2.02.||RESULTS OF OPERATIONS AND FINANCIAL CONDITION.|
In connection with remarks to be made at the J.P. Morgan 32nd Annual Healthcare Conference in San Francisco on Tuesday, January 14, 2014, beginning at 3:30 p.m. (pacific time), DexCom, Inc. (DexCom) Chief Executive Officer Terry Gregg will report estimated, unaudited product revenues for DexCom of approximately $51 million for the fourth quarter of 2013, up approximately 20% sequentially from the prior quarter and up approximately 61% from the fourth quarter of 2012. Estimated, unaudited product revenue for fiscal year 2013 was approximately $157 million, up approximately 69% from fiscal year 2012. Mr. Gregg will also disclose that since the launch of the G4 Platinum system in October 2012 through December 31, 2013, DexCom sold approximately 60,000 receivers, of which approximately 10% were sold to patients who had previously purchased a G4 Platinum receiver. Additionally, since the launch of the G4 Platinum system in October 2012 through December 31, 2013, DexCom sold approximately 1.5 million G4 Platinum sensors. Finally, Mr. Gregg will provide an estimated range for DexComs fiscal year 2014 product revenue of $205 million - $225 million.
Mr. Greggs presentation, which will occur live at the Westin St. Francis Hotel in San Francisco, will be concurrently webcast. The link to the webcast will be available on the DexCom website at www.dexcom.com under the investor relations events and webcasts section.
The fourth quarter 2013 unaudited financial results contained in Mr. Greggs presentation and in this report are subject to finalization in connection with the preparation of DexComs Annual Report on Form 10-K for the three and twelve months ended December 31, 2013. This report contains, and Mr. Greggs presentation on January 14, 2014 will contain, forward-looking statements concerning DexComs expectations, plans, anticipations, intentions, estimates, beliefs, potential or strategies regarding the future or the negative of these terms or other comparable terminology, including those related to DexComs expected revenue, product demand and financial performance. These forward-looking statements are based on DexComs current expectations and beliefs concerning future developments and their potential effects on it. There can be no assurance that future developments affecting DexCom will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond DexComs control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks associated with DexComs dependence on its G4 Platinum system; DexComs ability to increase customer orders; product performance; DexComs ability to obtain regulatory approval for and commercially launch new ambulatory products, expanded indications for use of current and future ambulatory products, and new products with DexComs insulin pump partners; a lack of acceptance in the marketplace by physicians and patients; DexComs ability to develop and manage its sales and marketing organization; adverse changes in general economic conditions; adverse regulatory or legal actions relating to the G4 Platinum ; possible delays in DexComs research and development programs or product approvals; potential supply problems or price fluctuations with sole source or other third-party suppliers on which DexCom is dependent; the inability to reliably manufacture products in commercial quantities at an acceptable cost; DexComs inability to raise additional funds in the future on acceptable terms or at all; impact of healthcare reform legislation; the inability of patients to receive reimbursements from third-party payors; the rising share of healthcare costs borne by patients; DexComs ability to protect its intellectual property and other proprietary rights and to defend against the patent infringement lawsuit filed by Abbott Diabetes Care, Inc.; the potential violation of federal or state laws prohibiting kickbacks or protecting patient health information, or any challenges to or investigations into DexComs practices under these laws; product liability lawsuits that may be brought against us; unfavorable results of clinical studies relating to the next generation ambulatory system, expanded indications for use for current generation products, or DexComs in-hospital product; DexComs ability to attract and retain key personnel; DexComs ability to manage growth; ability to integrate acquisitions of products and technologies; fluctuations in quarterly results of operations; and other risks and uncertainties described in DexComs Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 21, 2013, as amended, in the section entitled Risk Factors, as well as in DexComs most recent Quarterly Report on Form 10-Q in the section entitled Risk Factors, which was filed with the Securities and Exchange Commission on November 6, 2013. Should one or more of these risks or uncertainties materialize, or should any of DexComs assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. DexCom undertakes no obligation to publicly update or revise any forward-looking statements.
The information in this report is furnished pursuant to Item 2.02 of Form 8-K, and is not deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section. The information contained herein is not incorporated by reference in any filing of DexCom under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filings.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
/s/ Steven R. Pacelli
|Steven R. Pacelli|
|Executive Vice President, Strategy and Corporate Development|
Date: January 14, 2014